IPP Bureau
Briefs: Sun Pharma and Venus Remedies
By IPP Bureau - December 04, 2025
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies
By IPP Bureau - December 04, 2025
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech
By IPP Bureau - December 04, 2025
Stratasys completes US rollout of RadioMatrix 3D-printed imaging support material
By IPP Bureau - December 04, 2025
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Philips unveils helium-free 3.0T MRI innovation at RSNA 2025
By IPP Bureau - December 04, 2025
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Zuellig Pharma launches advanced clinical trial facility in South Korea
By IPP Bureau - December 04, 2025
Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
By IPP Bureau - December 04, 2025
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Aptar acquires Brazilian pharma packaging firm Sommaplast
By IPP Bureau - December 04, 2025
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
By IPP Bureau - December 04, 2025
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules
By IPP Bureau - December 04, 2025
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
By IPP Bureau - December 04, 2025
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Eli Lilly pledges $40 million to Indiana University to expand clinical trials
By IPP Bureau - December 04, 2025
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
By IPP Bureau - December 04, 2025
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Roche launches first rapid point-of-care test for whooping cough
By IPP Bureau - December 04, 2025
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
BPL Medical Technologies unveils critical-care innovations at ISACON 2025
By IPP Bureau - December 04, 2025
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
